Showing 2641-2650 of 3547 results for "".
Examining the Implications of Stage 2 of the EHR Incentive Program
https://practicaldermatology.com/topics/practice-management/examining-the-implications-of-stage-2-of-the-ehr-incentive-program/21564/Requirements for patient involvement via portals may spell headaches for physicians hoping to qualify for government incentives in 2014.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21961/Dermatology Q&A: First Head-to-Head Data Highlight Safety and Efficacy of Biologics
https://practicaldermatology.com/topics/psoriasis/first-head-to-head-data-highlight-safety-and-efficacy-of-biologics/22032/A lead investigator on the first head-to-head trial of biologics shares insights on the future of biologic research and therapy.Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
https://practicaldermatology.com/programs/cme/hitting-the-target-in-atopic-dermatitis-interdisciplinary-team-training-for-leveraging-il-13-inhibitors-to-address-the-burden-of-disease/54437/On-demand webcast on the role of interleukin (IL)-13 in atopic dermatitis pathophysiology and strategies for leveraging IL-13 inhibitors to address disease burden and improve patient outcomes.Rediscovering Topical Antifungal Therapy for Onychomycosis
https://practicaldermatology.com/topics/hair-nails/rediscovering-topical-antifungal-therapy-for-onychomycosis/22974/A number of potential topical therapies for onychomycosis have failed clinical investigation. Do we at last have a viable alternative to oral treatment options?An Overview of Topical Therapies for Managing Pediatric AD
https://practicaldermatology.com/topics/atopic-dermatitis/an-overview-of-topical-ththerapies-for-managing-pediatric-ad/54375/Moisturization is foundational in AD management; no specific formulation has demonstrated superiority, and excessive bathing may worsen disease via increased transepidermal water loss. Topical corticosteroids and calcineurin inhibitors remain first-line due to strong efficacy data, cost-effectiveneIn the Mind of Today’s Cosmetic Consumer
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/in-the-mind-of-todays-cosmetic-consumer/23102/Who is your cosmetic patient and how will they interact with your practice? Experts weigh in.New Products and Pharmacological Developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacological-developments/20345/Update on the Treatment of Actinic Keratoses
https://practicaldermatology.com/topics/general-topics/update-on-the-treatment-of-actinic-keratoses/21630/From mainstay therapies to newly approved agents, treatment options for actinic keratoses are growing.Get More of the Patients You Want
https://practicaldermatology.com/topics/practice-management/get-more-of-the-patients-you-want/20520/How to use micro-targeted digital marketing to grow your practice.